Published in Medical Letter on the CDC and FDA, August 14th, 2005
TZP-101 is a small molecule ghrelin receptor agonist, which has been shown to selectively stimulate motility of the GI tract. In a presentation at the 20th International Symposium on Neurogastroenterology & Motility (Toulouse, France), Tranzyme Pharma presented new in vivo data demonstrating that the potent and selective gastroprokinetic activity of TZP-101 takes place without the release of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA